Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: Synthesis and structure-activity relationship

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 4, 2000, Pages 373-375

  Yanagisawa, Hiroaki ^a   Takamura, Makoto ^a   Yamada, Eriko ^a   Fujita, Sachie ^a   Fujiwara, Toshihiko ^a   Yachi, Makoto ^a   Isobe, Aya ^a   Hagisawa, Yuka ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 BENZYL 2,4 THIAZOLIDINEDIONE DERIVATIVE; AROMATIC COMPOUND; BRIDGED COMPOUND; METHYL GROUP; OXIME DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BLOOD GLUCOSE; DRUG EVALUATION; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISOMERISM; MICE; MICE, INBRED STRAINS; OXIMES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 0034696095     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00003-2     Document Type: Article

References (16)

1. Porte D. Jr., Schwartz M.W. Science. 272:1996;699.
2. Feldt-Rasmussen B., Mathiesen E.R., Deckert T. Lancet. II:1986;300.
3. Dahl-Jørgensen K., Brinchmann-Hansen O., Hanssen K.F., Ganes T., Kierulf P., Smeland E., Sandvik L., Aagenaes Ø. Br. Med. J. 293:1986;1195.
4. The Diabetes Control and Complications Trial Research Group New Engl. J. Med. 329:1993;977.
5. Isley W.L. Drugs Today. 26:1990;59.
6. UK Prospective Diabetes Study Group. Diabetes 1995, 44, 1249.
7. Melander A., Bitzén P.-O., Faber O., Groop L. Drugs. 37:1989;58.
8. Yoshioka T., Fujita T., Kanai T., Aizawa Y., Kurumada T., Hasegawa K., Horikoshi H. J. Med. Chem. 32:1989;421.
9. Momose Y., Meguro K., Ikeda H., Hatanaka C., Oi S., Sohda T. Chem. Pharm. Bull. 39:1991;1440.
10. Cantello B.C.C., Cawthorne M.A., Cottam G.P., Duff P.T., Haigh D., Hindley R.M., Lister C.A., Smith S.A., Thurlby P.L. J. Med. Chem. 37:1994;3977.
11. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. J. Biol. Chem. 270:1995;12953.
12. Berger J., Bailey P., Biswas C., Cullinan C.A., Doebber T.W., Hayes N.S., Saperstein R., Smith R.G., Leibowitz M.D. Endocrinology. 137:1996;4189.
13. Hulin B., McCarthy P.A., Gibbs E.M. Curr. Pharm. Des. 2:1996;85.
14. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Nature. 395:1998;137.
15. Willson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., Lermann J.M. J. Med. Chem. 39:1996;665.
16. 50 equals the concentration of compound required to induce 50% of the maximum luciferase activity. All values are the mean of n=4.